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ABSTRACT toxic epidermal necrolysis (teN) is severe cutaneous hypersensitivity reaction 
characterized by necrosis of the epidermis and detachment of the epidermis and dermis 
that usually occurs as an idiosyncratic reaction to certain drugs. We report the case of a 
patient admitted to our Intensive Care Unit after an above-the-knee amputation who de-
veloped toxic epidermal necrolysis, possibly resulting from antibiotics therapy. therapy 
included a combination of intravenous immunoglobulin with gentle early debridement 
of necrotic skin areas followed by wound coverage with a synthetic cover (Aquacel Ag®). 
this case report suggests that intensive wound management together with intravenous 
immunoglobulin might be beneficial in the treatment of patients with teN.
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INTRODUCTION
toxic epidermal necrolysis (teN) is a severe cu-
taneous hypersensitivity reaction characterized by 
necrosis of the epidermis and detachment of the epi-
dermis and dermis followed by fever (1). When less 
than 10% of the skin is affected, the condition is called 
steven-Johnson syndrome (sJs), and when affected 
skin covers 10%-30% of the body it is called sJs/teN 
overlap. teN is the most severe clinical manifestation 
of sJs that affects more than 30% of the patient’s skin. 
Many groups of medications have been recognized 
as possible causes (2). Although the exact mechanism 
is unknown, it has been suggested that the main 
cause of teN is damage to the metabolic pathway of 
the drug being used, which leads to accumulation of 
toxic drug metabolites. these metabolites may have 
direct toxic effects or may act as haptens that interact 
with host tissues (3,4). the incidence is 2-7 cases per 
million, and mortality rates range from approximate-
ly 20% to 60% (5,6). the score for toxic epidermal 
Necrolysis (sCoRteN) can be used to predict patient 
outcomes (7). Management of teN requires prompt 
recognition and immediate withdrawal of all poten-
tial causative agents. Although there are no thera-
peutic guidelines regarding its management, and 
various treatment modalities have been suggested, 
such as corticosteroids, intravenous immunoglobulin 
therapy (IVIG), cyclosporine, cyclophosphamide, N-
acetylcysteine, plasmapheresis, etc., admission to an 
intensive care unit (ICU) or burn center together with 
supportive measures and wound care are considered 
crucial in teN treatment. It is known that adequate 
debridement of necrotic tissue with placement of 
wound coverage and admission to a burns or inten-
sive care unit improves survival and reduces infection, 
whereas specific treatment with immunosuppressive 
drugs, corticosteroids, or immunoglobulin did not re-
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As mentioned previously, no standard guidelines 
exist for the management of teN, but recently pub-
lished articles pointed out that combination treat-
ment with systemic steroids and immunoglobulin 
as well as supportive treatment seems to have con-
tributed to an evident prognostic improvement and 
remarkable recovery (9-11).
this case report highlights the importance of in-
tensive wound care and also suggests that IVIG might 
be beneficial in the treatment of patients with teN. 
CASE REPORT
A 77-year-old female was admitted to our hos-
pital to an Internal Medicine Department with fever 
and severe right limb infection after transmetatarsal 
amputation. she had a medical history of hyperten-
sion, hyperlipidemia, diabetes mellitus type II, su-
praventricular and ventricular extrasystolia, and se-
vere atherosclerosis. Further investigations showed 
inflammatory syndrome, anemia, uroinfection, and 
mild renal impairment, a consequence of fever and 
dehydration in the context of diabetes.
Based on the ambulatory-based antibiogram, 
first-line antibiotic treatment with vancomycin at 2 g/
day was continued for a total of 13 days, followed by 
piperacillin-tazobactam 2.25 g IV q8h for the next 15 
days. After that, the antibiotics were excluded from 
the therapy because inflammatory markers where 
normal and the patients had no fever. However, de-
spite early targeted antimicrobial therapy and se-
rial surgical debridement of the infected tissues, the 
patient’s general condition gradually deteriorated. 
she became febrile again with elevated C-reactive 
protein (CRp) and white blood cell count. Cultures 
of swabs obtained from the infected areas revealed 
methicillin-resistant Staphylococcus aureus (MRsA) 
and Citrobacter freundii which was resistant to piper-
acillin-tazobactam but sensitive to meropenem. the 
therapy with intravenous meropenem at 3 g/day 
and again with vancomycin at 2 g/day was started. 
After surgical examination and consultation, a trans-
femoral amputation was recommended. A preop-
erative assessment was performed on the patient 
by the consultant anesthetist. Clinical examination 
revealed multiple confluent macular erythema and 
bullous detachment of the epidermis over the face, 
trunk, and extremities, but predominantly on the 
chest and back. An otorhinolaryngologist who was 
consulted because of sore throat and swallowing dif-
ficulty noticed multiple painful buccal aphthous-like 
ulcerations. Above-knee amputation was performed 
2 days later under general anesthesia. After surgery, 
the patient was admitted to the ICU. she was in poor 
general condition upon admission: febrile with a 
temperature of 38.5 °C, pulse between 120140/min-
ute and with CRp 251 mg/L. During the patient’s stay 
in the ICU, skin lesions continued to progress; and 
epidermal detachment progressed over the next two 
days, and macular erythema and bullous skin lesions 
affected more than 50% of the total body surface 
area (tBsA) (Figure 1 and 2). severe oral involve-
ments also continued to progress in the form of 
Figure 1. peeling of the affected skin. Figure 2. peeling of the affected skin. 
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painful hemorrhagic erosions and crusting over the 
lips, restricting her oral intake. the rapid progression 
of the oral erosions and desquamation on most of the 
patient’s body surface area led us to suspect teN as 
the diagnosis. since it was assumed that the antibiot-
ics caused teN, all antibiotics were excluded from the 
therapy. Because of the severity of teN – the sCoRteN 
score was 4 (Age >40, glucose >250 mg/dL, heart rate 
>120/min, compromised body surface >10%) indi-
cating a 58.3% mortality rate – the patient was given 
intravenous immunoglobulin therapy 1 g/kg over 3 
days. she also received fluid resuscitation, and the 
wounds were treated with Aquacell® Ag (Convatec) 
and vaseline gauzes (Figure 3 and  4). the dressings 
were changed periodically following cleaning with 
saline and gentle debridement of exfoliated epider-
mis (Figure 5 and 6). After 15 days of local therapy, 
almost full re-epithelialization was achieved (Figure 
7 and 8), and the patient was generally in good con-
dition, without active inflammatory changes. A few 
days later, despite improvement, she developed a 
sudden bradycardia that did not respond to reanima-
tion procedures. the patients died after 18 days in the 
ICU from a massive heart attack, according to autopsy 
reports.
DISCUSSION
teN is a severe life-threatening pathological syn-
drome with a high mortality rate. Half of the deaths 
occur due to the secondary infection and subsequent 
sepsis and multi-organ system failure. As mentioned 
above, the pathogenesis of teN is not fully under-
stood but is believed to be an immune-related cyto-
toxic reaction against the offending drug or its me-
tabolites. Drugs can stimulate the immune system by 
binding directly and reversibly to immune receptors. 
the prevalence of antibiotics being responsible for 
teN ranges from 29% to 42% (12). Almost all antibiot-
ics have been implicated, but beta-lactam and sulfon-
amide are most commonly associated with teN, and 
teN usually develops within the first week of antibiot-
ic therapy. In our case, teN was diagnosed based on 
the clinical picture, and drugs we most suspected as 
the cause were antibiotics, due to the direct relation 
Figure 4. Lining placement.
Figure 3. Lining placement. 
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Figure 5. Removal of dead skin.
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between the onset of the disease and the administra-
tion of an antibiotic. our patient received antibiotics 
three days before the full clinical picture was evident. 
However, since the patient was receiving multiple an-
tibiotics, it was difficult to determine which antibiotic 
was causing the skin reaction. An improvement in the 
general condition of our patient after the withdrawal 
of antibiotics may provide indirect evidence for a 
causative role of antibiotics as a potential agent for 
teN in our case.
At the present time there is no uniform thera-
peutic strategy for teN, but recommendations are 
mostly conservative, so based on previous work and 
suggested recommendations we chose to treat the 
patient with the combination of intravenous immu-
noglobulin and regular and meticulous wound care. 
It appears that aggressive debridement should be 
restricted unless absolutely necessary. For regular 
wound care we used Aquacel Ag® – a primary wound 
dressing containing 1.2% silver in an ionic form dis-
tributed throughout the entire hydrofiber material. It 
is well known that silver ions possess potent broad-
spectrum antibacterial properties. the use of Aquacel 
Ag® in the local treatment of the patient resulted in 
faster epithelization of the skin surface and decreased 
fluid loss through skin layers. 
Despite controversy about the benefit on the use 
of IVIG, rapid progression of the skin lesions resulted 
in our ICU team’s decision to treat the patient with 
IVIG. An objective response to IVIG infusion was ob-
served within 48 h, and reepithelization was almost 
fully achieved after 15 days of combination of local 
therapy and IVIG.
the action mechanism of IVIG is complex and in-
volves several mechanisms. one of proposed mecha-
nisms involves the inhibition of keratinocyte death. 
Apoptotic keratinocyte cell death leads to separation 
of the epidermis from the dermis, with subsequent 
desquamation of skin. the rationale for using IVIG in 
patients with teN is to block keratinocyte apoptosis. 
Namely, a significant increase in immunoglobulin G 
(IgG) concentration in the serum, blister fluid, and 
epidermis was found in patients being treated with 
IVIG. elevated levels of IgG were found in clinically 
affected and unaffected skin, which means that IVIG 
has both systemic and local effects (13).
CONCLUSION
our case report shows that antibiotics are capable 
of inducing fatal adverse effects such as teN and sug-
gests that it might be beneficial to use a combination 
of Aquacel Ag® and IVIG in the treatment of patients 
with teN. Use of Aquacel Ag® helps rapid re-epitheli-
zation and prevents wound infection.
Consent
Verbal informed consent was obtained from the 
patient for the publication of this case report and the 
accompanying images. 
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Figure 6. Removal of dead skin.
Figure 8. Re-epithelialization
Figure 7. Re-epithelialization
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